IRIS
SALPINI, ROMINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.580
AS - Asia 3.850
EU - Europa 3.333
SA - Sud America 634
AF - Africa 104
OC - Oceania 90
Continente sconosciuto - Info sul continente non disponibili 11
Totale 27.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.449
SG - Singapore 1.872
IT - Italia 758
CN - Cina 739
BR - Brasile 504
RU - Federazione Russa 475
HK - Hong Kong 369
DE - Germania 355
VN - Vietnam 313
FI - Finlandia 258
FR - Francia 254
IE - Irlanda 247
PL - Polonia 206
UA - Ucraina 203
SE - Svezia 170
GB - Regno Unito 158
JP - Giappone 140
KR - Corea 107
AU - Australia 84
IN - India 79
CA - Canada 71
ES - Italia 66
AR - Argentina 52
NL - Olanda 51
MX - Messico 40
BD - Bangladesh 36
TR - Turchia 35
CZ - Repubblica Ceca 34
ID - Indonesia 33
ZA - Sudafrica 29
AT - Austria 28
IQ - Iraq 22
CO - Colombia 20
BE - Belgio 16
EC - Ecuador 16
MA - Marocco 14
VE - Venezuela 14
PH - Filippine 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
NG - Nigeria 11
PK - Pakistan 11
CL - Cile 9
EG - Egitto 9
BG - Bulgaria 8
KE - Kenya 8
NP - Nepal 8
PY - Paraguay 8
TN - Tunisia 8
DZ - Algeria 7
UZ - Uzbekistan 7
CM - Camerun 6
IR - Iran 6
LT - Lituania 6
NZ - Nuova Zelanda 6
PE - Perù 6
PT - Portogallo 6
RO - Romania 6
SA - Arabia Saudita 6
EU - Europa 5
JO - Giordania 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BB - Barbados 4
JM - Giamaica 4
KZ - Kazakistan 4
MY - Malesia 4
DK - Danimarca 3
GR - Grecia 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
KH - Cambogia 3
LK - Sri Lanka 3
MN - Mongolia 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HU - Ungheria 2
KG - Kirghizistan 2
OM - Oman 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
LB - Libano 1
Totale 27.591
Salva come PNG Salva come JPEG
Città #
Wilmington 4.613
Woodbridge 4.351
Houston 3.878
Singapore 1.127
Fairfield 737
San Jose 543
Ashburn 513
Chandler 487
Ann Arbor 385
Hong Kong 363
Beijing 290
Seattle 279
Rome 258
Cambridge 240
New York 229
Dublin 208
Helsinki 196
Jacksonville 161
Council Bluffs 158
Kraków 157
Santa Clara 151
The Dalles 146
Los Angeles 144
Medford 136
Tokyo 123
Milan 108
Dearborn 101
Ho Chi Minh City 97
Hanoi 86
Munich 78
Buffalo 65
Lawrence 65
Moscow 58
Dallas 57
Nuremberg 57
San Diego 56
Lauterbourg 52
São Paulo 47
London 44
Chicago 42
Orem 40
Menlo Park 39
Warsaw 33
Melbourne 30
San Francisco 30
Sydney 30
Zhengzhou 30
Stockholm 28
Chennai 27
La Veta 27
Mülheim 27
Denver 25
Jakarta 24
Redondo Beach 24
Toronto 23
Brooklyn 22
Creede 22
Montreal 22
Palo Alto 22
Johannesburg 21
Poplar 21
North Bergen 20
Amsterdam 19
Canberra 19
Frankfurt am Main 19
Naples 19
Phoenix 19
Brno 18
Atlanta 17
Lappeenranta 17
Washington 17
Engelhard 16
Guangzhou 16
Madrid 16
Boston 15
Brussels 15
Cedarhurst 15
Haiphong 15
Seoul 15
Verona 15
Vienna 15
Bari 14
Colorado Springs 14
Olomouc 14
Redwood City 14
Shanghai 14
Boardman 13
Brasília 13
Mexico City 13
Falls Church 12
Genoa 12
Manchester 12
Pittsburgh 11
Barcelona 10
Biên Hòa 10
Mumbai 10
Paris 10
Rio de Janeiro 10
Istanbul 9
Nanjing 9
Totale 22.014
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 574
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 507
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 506
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 485
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 479
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 477
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 473
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 468
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 457
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 453
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 450
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 450
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 442
Molecular analysis of hepatitis B virus in Bulgaria 439
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 433
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 426
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 424
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 422
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 421
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 420
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 418
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 418
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 418
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 409
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 409
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 407
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 407
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy 404
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 404
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 403
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 402
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 399
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 398
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 392
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 379
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 379
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 361
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 355
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 333
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 293
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis 276
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 266
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 262
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe 259
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 251
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 249
Different patterns of HIV-1 replication in MACROPHAGES is led by co-receptor usage 231
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 207
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 206
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 197
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 195
Reliable timescale inference of HBV genotype A origin and phylodynamics 180
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 175
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 174
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 170
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 161
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 158
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 153
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 151
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 142
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 141
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 135
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 127
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 121
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 121
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 119
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 113
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection. 107
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 104
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 103
Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome. 101
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 100
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 98
First National Prevalence in Italian Horse Population and Phylogenesis Highlight a Fourth Sub-Type Candidate of Equine Hepacivirus 96
Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection 94
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 90
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 89
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 88
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 88
SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays 87
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 87
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 87
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 86
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 86
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach 86
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs 85
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort 85
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 84
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 83
Amino acid variability of small molecule inhibitors and mAbs target sites in globally circulating RSV strains 82
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 79
Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients 78
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression. 78
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 78
POTENT ANTIVIRAL ACTIVITY OF NEW GENERATION HIV-1 MATURATION INHIBITORS ON HUMAN PRIMARY CELLS 76
Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach 76
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 74
Totale 25.947
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.609
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.609
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021154 0 0 0 0 0 0 0 0 0 0 111 43
2021/2022987 56 59 47 43 34 86 54 35 289 49 27 208
2022/20231.272 120 114 103 139 122 238 87 106 104 16 98 25
2023/2024910 163 26 95 50 90 143 44 17 57 83 21 121
2024/20253.066 110 583 306 213 127 235 336 174 346 218 209 209
2025/20265.765 568 252 556 549 591 296 839 764 748 583 19 0
Totale 28.196